PMID- 34825602
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20211214
IS  - 1552-695X (Electronic)
IS  - 1534-7354 (Print)
IS  - 1534-7354 (Linking)
VI  - 20
DP  - 2021 Jan-Dec
TI  - Radiosensitizing Effect of Bromelain Using Tumor Mice Model via Ki-67 and PARP-1 
      Inhibition.
PG  - 15347354211060369
LID - 10.1177/15347354211060369 [doi]
LID - 15347354211060369
AB  - Recent reports have shown that bromelain (BL), a pineapple extract, acts as an 
      adjuvant therapy in cancer treatment and prevention of carcinogenesis. The 
      present study was designed to investigate the possible mechanisms by which BL 
      could radiosensitize tumor cells in vitro and in a mouse tumor model. BL has 
      shown a significant reduction in the viability of the radioresistant human breast 
      carcinoma (MCF-7) cell line using cell proliferation assay. The in vivo study was 
      designed using the Ehrlich model in female albino mice, treated with BL (6 mg/kg 
      b. wt., intraperitoneal, once daily for 10 days) 1 hour before exposure to a 
      fractionated dose of gamma radiation (5 Gy, 1 Gy for 5 subsequent days). The 
      radiosensitizing effect of BL was evident in terms of a significant reduction in 
      tumor volume, poly ADP ribose polymerase-1 (PARP-1), the proliferation marker 
      Ki-67 and nuclear factor kappa activated B cells (NF-kappaB) with a significant 
      elevation in the reactive oxygen species (ROS) content and lipid peroxidation 
      (LPO) in tumor cells. The present findings offer a novel insight into the 
      radiosensitizing effect of BL and its potential application in the radiotherapy 
      course.
FAU - Mekkawy, Mai H
AU  - Mekkawy MH
AUID- ORCID: 0000-0002-1517-2548
AD  - National Centre for Radiation Research and Technology (NCRRT), Egyptian Atomic 
      Energy Authority, Nasr City, Cairo, Egypt.
FAU - Fahmy, Hanan A
AU  - Fahmy HA
AUID- ORCID: 0000-0002-9593-9664
AD  - National Centre for Radiation Research and Technology (NCRRT), Egyptian Atomic 
      Energy Authority, Nasr City, Cairo, Egypt.
FAU - Nada, Ahmed S
AU  - Nada AS
AD  - National Centre for Radiation Research and Technology (NCRRT), Egyptian Atomic 
      Energy Authority, Nasr City, Cairo, Egypt.
FAU - Ali, Ola S
AU  - Ali OS
AD  - Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Integr Cancer Ther
JT  - Integrative cancer therapies
JID - 101128834
RN  - 0 (Ki-67 Antigen)
RN  - 0 (NF-kappa B)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - 0 (Radiation-Sensitizing Agents)
RN  - 9001-00-7 (Bromelains)
SB  - IM
MH  - Animals
MH  - *Bromelains/pharmacology
MH  - Female
MH  - Ki-67 Antigen
MH  - Mice
MH  - NF-kappa B
MH  - Poly(ADP-ribose) Polymerase Inhibitors
MH  - *Radiation-Sensitizing Agents/pharmacology
PMC - PMC8649096
OTO - NOTNLM
OT  - Ehrlich
OT  - MCF-7
OT  - bromelain
OT  - gamma radiation
OT  - radiosensitizing effect
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2021/11/27 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/11/26
CRDT- 2021/11/26 08:37
PHST- 2021/11/26 08:37 [entrez]
PHST- 2021/11/27 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/11/26 00:00 [pmc-release]
AID - 10.1177_15347354211060369 [pii]
AID - 10.1177/15347354211060369 [doi]
PST - ppublish
SO  - Integr Cancer Ther. 2021 Jan-Dec;20:15347354211060369. doi: 
      10.1177/15347354211060369.